drugset / Trial / NCT03662568
A Drug-drug Interaction (DDI) Study of Morphothiadine Mesilate/Ritonavir in Healthy Subjects
Non-randomizedCrossoverOpen-labelTreatment
Summary
The purpose of this study is to evaluate the drug-drug-interaction (DDI), pharmacokinetics (PK) and tolerability of Morphothiadine Mesilate/Ritonavir combined with Entecavir or Tenofovir Disoproxil Fumarate in healthy subjects
Timeline
- Start
- 2018-06-26
- Primary completion
- 2018-07-31
- Completion
- 2019-06-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ETV | Unknown | 0.5 mg | Oral |
| Subject | GLS4 | Other / unclassified | 120 mg | Oral |
| Subject | RTV | Unknown | 100 mg | Oral |
| Subject | TDF | Unknown | 300 mg | Oral |